CO6180500A2 - Composiciones de fenilalquilamino-carbamato - Google Patents

Composiciones de fenilalquilamino-carbamato

Info

Publication number
CO6180500A2
CO6180500A2 CO09037414A CO09037414A CO6180500A2 CO 6180500 A2 CO6180500 A2 CO 6180500A2 CO 09037414 A CO09037414 A CO 09037414A CO 09037414 A CO09037414 A CO 09037414A CO 6180500 A2 CO6180500 A2 CO 6180500A2
Authority
CO
Colombia
Prior art keywords
compound
carbon atoms
alkyl
atoms
hydrogen
Prior art date
Application number
CO09037414A
Other languages
English (en)
Inventor
Ramendra N Pardey
Tracey Mascaro
Aniruddha Railkar
James Mccool
Hinton Clark
Stanley Altan
Original Assignee
Janssen Pharmaceutca N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutca N V filed Critical Janssen Pharmaceutca N V
Publication of CO6180500A2 publication Critical patent/CO6180500A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una composición de un compuesto de fenilalquilamino-carbamato que comprende una mezcla de este compuesto y una cantidad efectiva de uno o más excipientes, en donde por lo menos un excipiente es fosfato dibásico de calcio dihidratado, en donde el fosfato dibásico de calcio dihidratado reduce la degradación del compuesto de fenilalquilamino-carbamato en la composición. 2.- La composición de conformidad con la reivindicación 1, caracterizada además porque el compuesto es un compuesto de la fórmula (I): o una forma del mismo, en donde: R es un miembro seleccionado del grupo que consiste en hidrógeno, alquilo de 1 a 8 átomos de carbono, alquilo inferior de 1 a 4 átomos de carbono, halógeno seleccionado de F, CI, Br y I, alcoxi inferior que contiene de 1 a 3 átomos de carbono, nitro, hidroxi, trifluorometilo y tioalcoxi que contiene de 1 a 3 átomos de carbono; x es un entero seleccionado de 1, 2, o 3, con la condición de que cuando x es 2 o 3, los R pueden ser iguales o diferentes; R1 y R2 pueden ser iguales o diferentes entre sí y se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo de 1 a 8 átomos de carbono, alquilo inferior de 1 a 4 átomos de carbono, arilo, arilalquilo y cicloalquilo de 3 a 7 átomos de carbono; alternativamente, R1 y R2 pueden estar unidos para formar un heterociclo de 5 a 7 miembros sustituido con un miembro seleccionado del grupo que consiste en hidrógeno, alquilo y arilo, en donde opcionalmente el heterociclo puede comprender 1 o 2 miembros de anillo adicionales de átomos de nitrógeno, y de 0 a 1 miembros de anillo de átomos de oxígeno.3.- La composición de conformidad con la reivindicación 2, caracterizada además porque dicho compuesto es el éster 2-amino-3-fenil-propílico del ácido carbámico.4.- La composición de conformidad con la reivindicación 2, caracterizada además porque dicho compuesto es el éster (2R)-2-amino-3-fenil-propílico del ácido carbámico.
CO09037414A 2006-10-13 2009-04-14 Composiciones de fenilalquilamino-carbamato CO6180500A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82934206P 2006-10-13 2006-10-13

Publications (1)

Publication Number Publication Date
CO6180500A2 true CO6180500A2 (es) 2010-07-19

Family

ID=39111348

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09037414A CO6180500A2 (es) 2006-10-13 2009-04-14 Composiciones de fenilalquilamino-carbamato

Country Status (19)

Country Link
US (1) US20080090902A1 (es)
EP (1) EP2079449A2 (es)
JP (1) JP2010506845A (es)
KR (1) KR20090082213A (es)
CN (1) CN101557804A (es)
AU (1) AU2007313017A1 (es)
BR (1) BRPI0719275A2 (es)
CA (1) CA2673487A1 (es)
CO (1) CO6180500A2 (es)
CR (1) CR10794A (es)
EA (1) EA200970377A1 (es)
GT (1) GT200900082A (es)
IL (1) IL198145A0 (es)
MX (1) MX2009003926A (es)
NI (1) NI200900053A (es)
NO (1) NO20091530L (es)
SV (1) SV2009003221A (es)
WO (1) WO2008048801A2 (es)
ZA (1) ZA200903283B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254899B2 (en) 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
MX2012005258A (es) 2009-11-06 2012-06-19 Sk Biopharmaceuticals Co Ltd El uso de un compuesto de carbamoilo para el tratamiento del trastorno de deficit de atencion/hiperactividad.
AU2010316172B2 (en) * 2009-11-06 2015-11-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102014615B1 (ko) 2013-03-12 2019-08-27 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경보호용 조성물
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
DK2968208T3 (da) 2013-03-13 2022-08-22 Jazz Pharmaceuticals Ireland Ltd Behandling af kataplexi
CN110638804A (zh) 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
CN110037995B (zh) * 2019-04-17 2021-07-06 石家庄龙泽制药股份有限公司 一种稳定的盐酸帕罗西汀片剂及其制备方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
IT202000013855A1 (it) 2020-06-10 2021-12-10 Flamma Spa Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342687A (en) * 1964-06-25 1967-09-19 Colgate Palmolive Co Oral preparation
US3420817A (en) * 1966-12-06 1969-01-07 Hoffmann La Roche 4,1,5-benzoxadiazocin-2-ons and processes for preparing same
US6372438B1 (en) * 1988-02-02 2002-04-16 The Regents Of The University Of California Human platelet-derived growth factor receptors
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DE69618663T2 (de) * 1996-10-10 2002-08-14 Sk Corp O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
CA2418038A1 (en) * 2000-08-28 2002-03-07 Synthon B.V. Paroxetine compositions and processes for making the same

Also Published As

Publication number Publication date
GT200900082A (es) 2010-02-24
SV2009003221A (es) 2010-04-15
EA200970377A1 (ru) 2009-10-30
NO20091530L (no) 2009-07-06
US20080090902A1 (en) 2008-04-17
EP2079449A2 (en) 2009-07-22
ZA200903283B (en) 2010-07-28
NI200900053A (es) 2010-02-01
WO2008048801A3 (en) 2008-06-05
MX2009003926A (es) 2009-06-26
IL198145A0 (en) 2009-12-24
JP2010506845A (ja) 2010-03-04
BRPI0719275A2 (pt) 2014-04-29
CA2673487A1 (en) 2008-04-24
AU2007313017A1 (en) 2008-04-24
WO2008048801A2 (en) 2008-04-24
KR20090082213A (ko) 2009-07-29
CR10794A (es) 2009-09-29
CN101557804A (zh) 2009-10-14

Similar Documents

Publication Publication Date Title
CO6180500A2 (es) Composiciones de fenilalquilamino-carbamato
CL2021002965A1 (es) Compuestos antivirales que contienen nitrilo.
AR054790A1 (es) Metodos para el tratamiento de disfuncion sexual
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
ES2082005T3 (es) Composicion anti-hipertensora de aductos de amina secundaria-oxido nitrico y uso de la misma.
CO6190539A2 (es) Composiciones de carbamato fenilalquilo
ES2183782T3 (es) Material de sutura para heridas a base de metilideno malonato.
PE20220905A1 (es) Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
PL387494A1 (pl) Ciekłe mieszaniny fosforynów jako stabilizatory
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
TW200612920A (en) Novel imidazolidine derivatives
CO5231190A1 (es) Combinaciones de compuestos activos del tipo de los cetoenoles ciclicos con piretroides
UY28821A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
AR054747A1 (es) Compuestos de indanil-piperazina un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CO5640075A2 (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
CO5690581A2 (es) Derivados de cicloalquilo 1,3-sustituidos que tienen grupos acidicos principalmente grupos heterociclicos; procedimientos para su preparacion y su uso como medicamentos
CO5580834A2 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
TW200942559A (en) New phosphate ester-based hydrophilic polyisocyanate compositions

Legal Events

Date Code Title Description
FC Application refused